万维提示：
1、该刊只有国际刊号。
2、投稿方式：在线投稿。
3、官网网址（微信公众号信息）：
https://www.sciencedirect.com/journal/eye-discovery
4、投稿系统：
https://www.editorialmanager.com/edisc/default2.aspx
5、官网邮箱：eyediscovery@fudan.edu.cn
6、出刊日期：官方暂未公布刊期信息。
7、官方微信公众号：Eye Discovery
8、微信公众号信息：2026-2028年，免收稿件处理费
2025年12月22日星期一
Call for Paper | Eye Discovery
【官方微信公众号信息】
Eye Discovery 2025年11月29日
《Eye Discovery》诚邀全球眼科科学家与临床工作者，加入这一高水平国际学术平台。提交您的最新研究成果，与世界各地同行共探眼科领域前沿！
Eye Discovery invites global ophthalmic scientists and clinicians to join its high-level international academic platform. Submit your latest findings to explore ophthalmic frontiers with peers worldwide!
关于我们
Aim & Scope
《Eye Discovery》是由复旦大学附属眼耳鼻喉科医院联合顶尖学术力量创办的开放获取、同行评审国际学术期刊。期刊致力于搭建高端平台，汇聚全球眼科医师、研究人员及学者，聚焦眼科学及交叉学科的创新成果，促进学术传播与交流。随着眼科新技术飞速发展并深刻影响临床实践，亟需专属学术载体整合突破性研究、推动学科创新，这也是《Eye Discovery》的核心使命。
Eye Discovery is an open-access, peer-reviewed international academic journal initiated by the Eye & ENT Hospital of Fudan University in collaboration with top academic forces. It is dedicated to creating a high-end platform for ophthalmologists, scientists, and scholars worldwide to focus on innovative achievements in ophthalmology and interdisciplinary fields, and to promote academic dissemination and exchange. With the rapid advancement of new ophthalmic technologies and their profound impact on clinical practice, there is an urgent need for a dedicated academic venue to integrate groundbreaking research and propel disciplinary innovation, which constitutes the core mission of Eye Discovery.
文章类型
Article Types
社论（Editorials）
原创研究（Original Articles）
综述（Reviews）
评论（Comments）
病例报告（Case Reports）
致编辑的信（Letters to the Editor）
潜在主题
Potential Topics
期刊欢迎涵盖眼科及相关交叉学科所有领域的原创研究与学术成果，包括但不限于：
各类眼科疾病的发病机制、诊断与治疗
眼科人工智能与数字诊断
眼科生物治疗（基因治疗、细胞治疗等）
纳米生物医学在眼科的应用
眼科相关交叉学科研究
Eye Discovery welcomes original research and academic achievements covering all areas of ophthalmology and related interdisciplinary disciplines, including but not limited to:Pathogenesis, Diagnosis and Treatment of Ophthalmic Diseases
Artificial Intelligence and Digital Diagnostics in Ophthalmology
Ophthalmic Biotherapies ( including Gene Therapy, Cell Therapy, etc.)
Nanobiomedicine Applications in Ophthalmology
Other Interdisciplinary Research in Ophthalmology
投稿及联系方式
Submission
期刊网址：https://www.scie ncedirect.com/journal/eye-discovery
Submit Your Manuscript：
https://www.editorialmanager.com/edisc/Default.aspx
Contact Email: eyediscovery@fudan.edu.cn
From 2026 to 2028, the article processing charge ( APC ) will be waived.
For submission-related questions, please contact the editorial office via the above email, and we will provide professional answers promptly.
Guide for authors
【官网信息】
About the journal
Aims and scope
Eye Discovery is an open access, peer-reviewed journal for ophthalmologists and scientists. It welcomes original articles, reviews, case reports, editorials, commentaries, perspectives, letters and short reports encompassing all aspects of ophthalmology/eye and its interdisciplinary disciplines. The swift advancement of new technology and its profound impact on ophthalmology necessitate a dedicated platform for the dissemination and exchange of scientific research outcomes.
Article types
Eye Discovery publishes:
Editorials should focus on significant advances, controversial issues, or influential clinical/research trends in ophthalmology, emphasizing insightful perspectives and critical analyses while avoiding extensive literature reviews. These concise commentaries have a maximum length of 800 words (excluding references) and should include complete author details (full names, affiliations, email addresses), a Conflict of Interest (COI) statement, and an Author Contributions statement.
Research articles report original, cutting-edge studies in ophthalmology, including experimental investigations, clinical observations, randomized controlled trials (RCTs). The submissions have a maximum 7,000 words (excluding title, references, tables, and figures) and requires a structured abstract of 300 - 500 words with Objective, Methods, Results, Conclusion sections, avoiding abbreviations and references. Authors should provide 3 - 8 keywords. Manuscripts should be submitted as a single text file containing the Title Page, Main text, Acknowledgements / Disclosure Statement, References, and Figure Legends. For randomized controlled trials, a completed CONSORT Worksheet must be submitted.
Reviews Article provide comprehensive synthesis of current evidence on significant ophthalmic topics (3,000 - 5,000 words including abstract, references, and figures/tables), which should offer original insights. All submissions require a 250-word abstract and should include high-quality figures/table where appropriate, with emphasis placed on recent references (preferably published within the last five years). Systematic reviews should additionally comply with PRISMA guidelines and PROSPERO registration number. Each submission must include complete author details (full names, affiliations, email addresses), a COI statement, and an Author Contributions statement.
Comments should provide evidence-based, constructive critique or scholarly debate concerning specific articles recently published in this journal, with a maximum 1,200 words including references). All submissions must bear the title ‘Comment on [Full Original Article Title]’ and include: (1) complete author details (full names, affiliations, email addresses); (2) a COI statement explicitly disclosing any relationships with authors of the original article; (3) an Author Contributions statement specifying individual inputs.
Case Reports document clinically significant individual cases or small case series (typically ≤5 cases) that demonstrate exceptional rarity, novel ophthalmic findings, or substantial educational value (maximum 1,200 words including main text, references, and figure legends). Submissions should include: (1) complete author details (full names, affiliations, email addresses); (2) a comprehensive manuscript with detailed case description and scholarly discussion; (3) high-quality diagnostic images with detailed legends; (4) COI statement and Author Contributions statement; and (5) documentation of patients consent and ethics committee approval (where applicable), which should be declared at submission and verified before publication.
Letters to the Editor offer concise commentary (maximum 500 words, excluding abstract, figures, tables, and references) that stimulates scholarly discussion concerning recent publications in this Journal or other significant ophthalmological research. All submissions should include a disclosure statement.
Peer review
This journal follows a review process. Your submission will initially be assessed by our editors to determine suitability for publication in this journal. If your submission is deemed suitable, it will typically be sent to a minimum of for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected will be taken by our editors.
Read more about peer review.
Our editors are not involved in making decisions about papers which:
they have written themselves.
have been written by family members or colleagues.
relate to products or services in which they have an interest.
Any such submissions will be subject to the journal's usual procedures and peer review will be handled independently of the editor involved and their research group. Read more about editor duties.
Authors may submit a formal appeal request to the editorial decision, provided it meets all the requirements and follows the procedure outlined in Elsevier’s Appeal Policy. Only one appeal per submission will be considered and the appeal decision will be final.
Open access
We refer you to our open access information page to learn about open access options for this journal.
Ethics and policies
Ethics in publishing
Authors must follow ethical guidelines stated in Elsevier's Publishing Ethics Policy.
Submission declaration
When authors submit an article to an Elsevier journal it is implied that:
the work described has not been published previously except in the form of a preprint, an abstract, a published lecture, academic thesis or registered report. See our policy on multiple, redundant or concurrent publication.
the article is not under consideration for publication elsewhere.
the article's publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out.
if accepted, the article will not be published elsewhere in the same form, in English or in any other language, including electronically, without the written consent of the copyright-holder.
To verify compliance with our journal publishing policies, we may check your manuscript with our screening tools.
Authorship
All authors should have made substantial contributions to all of the following:
The conception and design of the study, or acquisition of data, or analysis and interpretation of data.
Drafting the article or revising it critically for important intellectual content.
Final approval of the version to be submitted.
Authors should appoint a corresponding author to communicate with the journal during the editorial process. All authors should agree to be accountable for all aspects of the work to ensure that the questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Changes to authorship
The editors of this journal generally will not consider changes to authorship once a manuscript has been submitted. It is important that authors carefully consider the authorship list and order of authors and provide a definitive author list at original submission.
The policy of this journal around authorship changes:
All authors must be listed in the manuscript and their details entered into the submission system.
Any addition, deletion or rearrangement of author names in the authorship list should only be made prior to acceptance, and only if approved by the journal editor.
Requests to change authorship should be made by the corresponding author, who must provide the reason for the request to the journal editor with written confirmation from all authors, including any authors being added or removed, that they agree with the addition, removal or rearrangement.
All requests to change authorship must be submitted using this form. Requests which do not comply with the instructions outlined in the form will not be considered.
Only in exceptional circumstances will the journal editor consider the addition, deletion or rearrangement of authors post acceptance.
Publication of the manuscript may be paused while a change in authorship request is being considered.
Any authorship change requests approved by the journal editor will result in a corrigendum if the manuscript has already been published.
Any unauthorized authorship changes may result in the rejection of the article, or retraction, if the article has already been published.
......
更多详见：
https://www.sciencedirect.com/journal/eye-discovery/publish/guide-for-authors
